Key statistics
On Thursday, Uniqure NV (0EE0:LSE) closed at 5.06, 35.06% above the 52 week low of 3.74 set on Jul 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 5.06 |
Low | 5.06 |
Bid | -- |
Offer | -- |
Previous close | 4.96 |
Average volume | 4.83k |
---|---|
Shares outstanding | 48.70m |
Free float | 46.59m |
P/E (TTM) | -- |
Market cap | 234.72m USD |
EPS (TTM) | -5.92 USD |
Data delayed at least 20 minutes, as of Sep 26 2024 18:52 BST.
More ▼
- uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
- uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
- uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update
- uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
- uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
- uniQure Announces Sale of Commercial Manufacturing Facility to Genezen
- uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
- uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
- uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
- uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
More ▼